+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 462 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are investigating new treatment options for meningiomas that continue to grow despite local therapies like surgery or radiotherapy. This trial focuses on evaluating a precision medicine approach that combines PET-based imaging to select patients with tumors expressing somatostatin receptors and a targeted radioligand therapy called 177Lu-DOTATATE. This is the first randomized clinical trial studying this therapy in patients with meningiomas that have not responded to other treatments. Participants will be randomly assigned to one of two groups. One group receives 177Lu-DOTATATE through intravenous infusions every four weeks for a total of four cycles. The other group receives local standard care, which may include treatments like hydroxyurea, bevacizumab, sunitinib, octreotide, everolimus, or observation with supportive care, based on the investigators choice. This study is designed to compare the effects of 177Lu-DOTATATE against various standard treatments in this patient population. During the study, participants will undergo regular MRI scans to measure tumor size and progression. Researchers will also assess overall survival, neurological function, quality of life, and treatment side effects over a period extending up to two years after enrollment. Monitoring includes imaging, laboratory tests, and health questionnaires to evaluate how the disease and treatments affect participants over time.

Age: 18Years +All GendersPhase 2
19 locations
H

Actively Recruiting

Researchers are evaluating the use of high-resolution 7 Tesla MRI imaging of the spine to better distinguish bone spurs from disc material and to more clearly show compressed nerves in the neuroforamen compared to standard 3 Tesla MRI. This study aims to provide surgeons with detailed anatomical images before surgery, potentially reducing the need for CT scans when bone anatomy is crucial. Participants undergo a 7 Tesla MRI scan of the spine, which is a diagnostic imaging procedure. The study compares the 7 Tesla MRIs ability to differentiate compressed nerves with that of the 3 Tesla MRI over a two-year period. This observational study does not involve treatment but focuses on imaging evaluation. During the study, participants will have MRI scans and may provide informed consent for participation. Researchers will assess imaging details to measure how well the 7 Tesla MRI depicts nerve compression compared to standard imaging. The primary outcome is the differentiation of compressed nerves in the neuroforamen over two years. Participants involvement length and visit frequency depend on the imaging schedule and clinical needs.

Age: 18Years +All Genders
1 location
H

Actively Recruiting

Researchers are evaluating the use of high-resolution 7 Tesla MRI to examine the cervical spine with a focus on differentiating nerve roots and surrounding tissues within the neural foramina. This imaging also allows detailed assessment of the vertebral arterys anatomy and its relationship to nearby neural structures. The study aims to establish standard measurements of nerve roots, ganglia, and neuroforamen diameters as reference values. Participants will undergo 7 Tesla MRI scans to capture detailed images of their cervical spine. The study includes individuals over 18 years old who have chronic back pain lasting more than 2 months without recent trauma or prior MRI for clinical reasons, as well as asymptomatic participants to depict normal microanatomy. No treatments are administered, as this is an observational diagnostic imaging study. During the study, participants will be assessed through the MRI scans to measure nerve and ganglia diameters in millimeters and to evaluate the relationship between the vertebral artery and neural structures by checking for the presence of fat tissue between them. These measures will be recorded and analyzed over approximately one year. The study is sponsored by Balgrist University Hospital and will continue until September 2027.

Age: 18Years +All Genders
1 location
I

Actively Recruiting

Healthy Volunteer

Researchers are working to create and use a comprehensive database focused on intracranial aneurysms IA. This project collects and studies clinical history, imaging data, biological samples, and other information to understand factors linked to the formation and rupture of aneurysms. They aim to identify genetic, environmental, and anatomical markers, as well as evaluate outcomes from different treatment strategies and improve patient care protocols. Participants include patients with diagnosed aneurysms, both ruptured and unruptured, family members of affected individuals, and healthy volunteers. Data collected involves detailed clinical records, imaging scans like MRI angiography and CT angiography, and various biological samples such as blood, cerebrospinal fluid, saliva, and stool. Consent covers access to medical records, use of biological samples, and potential future research uses including genetic analyses. During the study, participants provide health and lifestyle information, imaging data, and biological samples. Researchers will monitor multiple long-term outcomes including disease progression, life expectancy, quality of life, neurological and cognitive status, and treatment effects over periods up to 20 years. Data confidentiality is maintained, and participants can withdraw at any time without affecting their medical care. The study aims to validate disease models and support advances in aneurysm management and research.

Age: 18Years +All Genders
22 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are investigating how electromagnetic fields EMFs from 5G technology affect sleep health, focusing on a specific brain protein called CaV1.2, a voltage-gated calcium channel. This protein may play a role in how 5G influences sleep, especially for people with a certain genetic variant. The study aims to see if blocking this channel with the drug nimodipine can reduce or stop the impact of 5G on sleep in healthy adults with the genetic variant. The study involves a large genetic screening to find participants with the targeted genetic variant, followed by a sleep screening night. Then, participants undergo four experimental nights where they are exposed to either an active 5G field or a sham inactive field, combined with either nimodipine or a placebo. The drug or placebo is given orally 45 minutes before exposure, and the study uses a double-blind design with 24 different sequences of drug and exposure combinations randomly assigned to participants. During the study nights, participants have their sleep monitored using polysomnography and high-density EEG during wakefulness. Researchers also measure heart rate, cognitive and neuropsychiatric functions, and various sleep characteristics like sleep spindle frequency and EEG power spectra. The study includes assessments before and after sleep, with at least three days between sessions to avoid overlap. The total duration covers screening, genetic testing, and multiple experimental sessions to understand the role of CaV1.2 in 5G effects on sleep.

Age: 20Years - 40YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating MammoWave, a device that uses low-power microwaves instead of X-rays, for early breast cancer detection in women aged 45 to 74. This prospective, multicenter clinical investigation aims to confirm that MammoWave achieves sensitivity greater than 75% and specificity greater than 90% for breast cancer detection among 10,000 volunteers undergoing regular screening programs. The study compares MammoWave results with conventional breast examination methods including mammograms and other radiological or histological tests. Participants will undergo both the standard breast screening exams and the MammoWave exam. The MammoWave exam involves lying prone on a bed while the device collects microwave data from both breasts over about 8 minutes. Data processing uses a special imaging algorithm to produce microwave images and classification results indicating suspicious or non-suspicious findings. The study device contains the same hardware as a CE-marked version but uses updated software. During the study, participants will have conventional breast exams along with the MammoWave exam. Researchers will evaluate MammoWaves sensitivity and specificity during the procedure and analyze detection rates, recall rates, and positive predictive values at baseline. Volunteers will also complete satisfaction questionnaires. The study will monitor breast cancer detection by histological type, size, and breast density. The trial is expected to run until December 2026.

Age: 45Years - 74YearsFEMALEPhase Not Applicable
10 locations
E

Actively Recruiting

Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.

Age: 18Years +All GendersPhase 3
221 locations
E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
M

Actively Recruiting

Researchers are evaluating NXT007 prophylaxis compared with Factor VIII FVIII prophylaxis in people aged 12 years and older who have severe or moderate congenital hemophilia A without FVIII inhibitors. The study aims to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 in preventing bleeds compared to the standard FVIII treatment. Participants must have been on FVIII prophylaxis before joining the trial. Participants will be randomly assigned to receive either NXT007 prophylaxis or FVIII standard of care prophylaxis during the main study treatment period lasting six months. NXT007 is given by subcutaneous injection using a drug-device combination product, while FVIII is administered according to local dosing guidelines. After this period, those on NXT007 may continue its dosing, and those originally on FVIII can switch to NXT007 in an open-label extension phase. During the study, participants will be monitored regularly for bleeding rates, treatment burden, and quality of life using questionnaires like CATCH and TASQ. Safety will be assessed through adverse event monitoring, including injection-site reactions and thromboembolic events. Blood samples will be collected to measure NXT007 levels and immune response over approximately 3.5 years. The main outcome measured is the annualized bleed rate for treated bleeds over six months.

Age: 12Years +All GendersPhase 3
36 locations
E

Actively Recruiting

Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.

Age: 50Years +All GendersPhase 2Phase 3
132 locations

1-10 of 462

1